LSE:GSK 25 April 2026 - 14 May 2026

GSK Stock Goes Ex-Dividend Today: Why the 17p Payout Comes With a Bigger Pipeline Test
····

GSK Stock Goes Ex-Dividend Today: Why the 17p Payout Comes With a Bigger Pipeline Test

GSK shares traded ex-dividend in London on May 14, with a 17 pence first-quarter payout due July 9. The company began the final tranche of its £2 billion buyback on May 11, having repurchased £1.82 billion so far. GSK signed a deal with Chia Tai Tianqing for bepirovirsen in China, where the drug is under priority review. Bepirovirsen is not yet approved; the FDA’s target decision date is Oct. 26, 2026.
May 14, 2026
GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus
·····

GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus

GSK has signed an exclusive deal with Sino Biopharmaceutical’s CTTQ unit to launch hepatitis B drug candidate bepirovirsen in China, gaining access to over 5,000 medical centres. CTTQ will handle importation, distribution, and promotion, while GSK retains regulatory control. Bepirovirsen is not yet approved anywhere. Financial terms were not disclosed.
May 13, 2026
GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight
······

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight

A U.S. judge dismissed Acuitas Therapeutics’ attempt to clear Pfizer and BioNTech’s Comirnaty vaccine of GSK patent claims, citing lack of jurisdiction, Bloomberg Law reported Friday. The decision keeps the focus on GSK’s main Delaware lawsuit alleging Comirnaty infringes mRNA-vaccine patents. Pfizer has pledged to defend its position. The ruling does not address whether infringement occurred.
May 9, 2026
GSK’s Jemperli Court Fight Just Got Tougher Before Q1 Earnings
······

GSK’s Jemperli Court Fight Just Got Tougher Before Q1 Earnings

A Delaware court dismissed Tesaro’s claim that AnaptysBio anticipatorily breached their Jemperli cancer-drug agreement, preserving Anaptys’ royalty rates. The ruling comes days before GSK’s first-quarter results, with Jemperli sales under scrutiny. Jemperli generated $1.128 billion in 2025 sales, according to Anaptys. The FDA expanded Jemperli’s use in endometrial cancer in 2024.
April 25, 2026

Stock Market Today

  • Hiscox Stock Targets Rise as Analysts Upgrade Fair Value and Capital Returns
    May 26, 2026, 7:41 PM EDT. Analysts have raised the fair value estimate for insurance firm Hiscox (LSE:HSX) from £16.06 to £16.90, with price targets now ranging between £16.11 and £18.00. Morgan Stanley increased its target to £18.00 maintaining an Overweight rating, while RBC Capital raised its target to £17.10 with an Outperform stance. Citi raised its target to £16.11 but kept a Neutral rating, reflecting cautious optimism. The upgrades highlight improved revenue growth assumptions, a higher net profit margin, and a slightly increased price-to-earnings (P/E) ratio forecast. However, the narrower target range suggests limited upside if execution falters. Investors should watch for risks and evolving narratives to gauge Hiscox's potential amid shifting analyst views and capital return strategies.